Baxter International Inc Declares Quarterly Dividend of $0.22 (NYSE:BAX)

Baxter International Inc (NYSE:BAX) declared a quarterly dividend on Tuesday, November 19th, RTT News reports. Stockholders of record on Friday, December 6th will be paid a dividend of 0.22 per share by the medical instruments supplier on Thursday, January 2nd. This represents a $0.88 annualized dividend and a dividend yield of 1.08%. The ex-dividend date of this dividend is Thursday, December 5th.

Shares of Baxter International stock opened at $81.86 on Tuesday. The stock has a market cap of $41.85 billion, a price-to-earnings ratio of 26.84, a PEG ratio of 2.11 and a beta of 0.98. The firm’s 50-day moving average is $81.66 and its 200 day moving average is $82.72. Baxter International has a 1 year low of $61.40 and a 1 year high of $89.93. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10.

In related news, SVP Jacqueline Kunzler sold 5,934 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $88.12, for a total value of $522,904.08. Following the sale, the senior vice president now owns 3,089 shares in the company, valued at $272,202.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Andrew Frye sold 3,332 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $88.00, for a total transaction of $293,216.00. Following the completion of the sale, the senior vice president now owns 16,391 shares in the company, valued at approximately $1,442,408. The disclosure for this sale can be found here. Insiders sold 9,446 shares of company stock valued at $831,917 over the last quarter. Company insiders own 0.70% of the company’s stock.

BAX has been the subject of several recent analyst reports. ValuEngine cut shares of Baxter International from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. set a $94.00 price target on shares of Baxter International and gave the company a “buy” rating in a report on Tuesday, October 8th. Piper Jaffray Companies reissued a “buy” rating on shares of Baxter International in a research report on Tuesday, September 10th. Finally, Deutsche Bank began coverage on shares of Baxter International in a research report on Monday, October 21st. They set a “buy” rating and a $109.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $89.77.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Read More: What is total return in investing?

Dividend History for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.